Decreased IP-10 and elevated TGFβ1 levels are associated with viral clearance following therapy in patients with hepatitis C virus

Disease Markers

Volumn 28, Issue 5, 2010, Pages 273-280

  Lee, Silvia ^a,b   Varano, Julius ^b   Flexman, James P ^a   Cheng, Wendy ^a   Watson, Mark W ^a   Rossi, Enrico ^c   Adams, Leon A ^d   Bulsara, Max ^b   Price, Patricia ^a,b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c PATHWEST LABORATORY MEDICINE   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

chemokines; fibrosis; Hepatitis C virus; interferon based therapy

Indexed keywords

CD30 ANTIGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 13 RECEPTOR ALPHA2; INTERLEUKIN 18; PEGATRON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; ALPHA INTERFERON; ALPHA2A INTERFERON; ANTIVIRUS AGENT; BETAIG-H3 PROTEIN; CXCL10 PROTEIN, HUMAN; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN; SCLEROPROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; FEMALE; FIBROGENESIS; HEPATITIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME; ALGORITHM; AREA UNDER THE CURVE; BLOOD; HEPACIVIRUS; LIVER CIRRHOSIS; MIDDLE AGED; PHYSIOLOGY; SENSITIVITY AND SPECIFICITY; VIROLOGY; VIRUS LOAD;

HEPATITIS C VIRUS;

ADULT; AGED; ALGORITHMS; ANTIVIRAL AGENTS; AREA UNDER CURVE; CHEMOKINE CXCL10; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; SENSITIVITY AND SPECIFICITY; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77954799159     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.3233/DMA-2010-0699     Document Type: Article

References (39)

1. L.A. Adams, M. Bulsara, E. Rossi et al., Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection, Clinical Chemistry 51 (2005), 1867-1873.
2. D.D. Anthony, A.B. Post, H. Valdez et al., ELISPOT analysis of hepatitis C virus protein-specific IFN-gamma-producing peripheral blood lymphocytes in infected humans with and without cirrhosis, Clinical Immunology 99 (2001), 232-240.
3. S.R. Bialek and N.A. Terrault, The changing epidemiology and natural history of hepatitisCvirus infection, Clinical Liver Disease 10 (2006), 697-715.
4. D.M. Bissell, D. Roulot and J. George, Transforming growth factor beta and the liver, Hepatology 34 (2001), 859-867.
5. I.S. Elefsiniotis, C. Pavlidis, I. Ketikoglou, S. Koutsounas, N. Scarmeas, K.D. Pantazis, A. Moulakakis and E.V. Tsianos, Patient's age modifies the impact of the proposed predictors of sustained virological response in chronic hepatitis C patients treated with PEG-interferon plus ribavirin, European J Internal Medicine 19 (2008), 266-270.
6. X. Forns, S. Ampurdaǹes, J.M. Llovet et al., Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model, Hepatology 36 (2002), 986-992.
7. M.M. George, S.D. Li, A.L. Mindikoglu et al., Platelet sparing effect of COX II inhibition used with pegylated interferon alfa- 2a for the treatment of chronic hepatitis C: a short term pilot study, Cytokine 27 (2004), 159-165.
8. C. Hanck, T. Manigold, U. Böcker et al., Gene expression of interleukin 18 in unstimulated peripheral blood mononuclear cells of patients with alcoholic cirrhosis, Gut 49 (2001), 106-111.
9. C.E. Harvey, J.J. Post, P. Palladinetti et al., Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation, J Leukocyte Biology 74 (2003), 360-369.
10. K.Q. Hu, J.M. Vierling and A.G. Redeker, Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection, J Viral Hepatology 8 (2001), 1-18.
11. F. Imbert-Bismut, V. Ratziu, L. Pieroni et al., Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study, Lancet 357 (2001), 1069-1075.
12. E. Janczewska-Kazek, B. Marek, D. Kajdaniuk and H. Borgiel-Marek, Effect of interferon alpha and ribavirin treatment on serum levels of transforming growth factor-beta1, vascular endothelial growth factor, and basic fibroblast growth factor in patients with chronic hepatitis C, World J Gastroenterology 12 (2006), 961-965.
13. M. Lagging, A.I. Romero, J.Westin et al., IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection, Hepatology 44 (2006), 1617-1625.
14. S. Lee, G.C. Macquillan, N.M. Keane et al., Immunological markers predicting outcome in patients with hepatitis C treated with interferon-alpha and ribavirin, Immunology Cell Biology 80 (2002), 391-397.
15. V. Leroy, M.N. Hilleret, N. Sturm et al., Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C, J Hepatology 46 (2007), 775-782.
16. I.S. Elefsiniotis, C. Pavlidis, I. Ketikoglou et al., Patient's age modifies the impact of the proposed predictors of sustained virological response in chronic hepatitis C patients treated with PEG-interferon plus ribavirin, Eur J Internal Medicine 19 (2008), 266-270.
17. O. Ludwiczek, A. Kaser, D. Novick et al., Plasma levels of interleukin-18 and interleukin-18 binding protein are elevated in patients with chronic liver disease, J Clinical Immunology 22 (2002), 331-337.
18. M. Martinot-Peignoux, L. Comanor, J.M. Minor et al., Accurate model predicting sustained response at week 4 of therapy with pegylated interferon with ribavirin in patients with chronic hepatitis C, J Viral Hepatology 13 (2006), 701-707.
19. M.M. Mentink-Kane and T.A. Wynn, Opposing roles for IL- 13 and IL-13 receptor alpha 2 in health and disease, Immunol Reviews 202 (2004), 191-202.
20. N. Masaki, S. Fukushima and S. Hayashi, Lower th-1/th-2 ratio before interferon therapy may favor long-term virological responses in patients with chronic hepatitis C, Digestive Disease Science 47 (2002), 2163-2169.
21. T. Murata, T. Ohshima, M. Yamaji et al., Suppression of hepatitis C virus replicon by TGF-beta, Virology 331 (2005), 407-417.
22. J. Nattermann, M. Vogel, H.D. Nischalke et al., The transforming growth factor-beta high-producer genotype is associated with response to hepatitis C virus-specific therapy in HIV-positive patients with acute hepatitis C, AIDS 22 (2008), 1287-1292.
23. M.G. Neuman, J.P. Benhamou, P. Marcellin et al., Cytokine- chemokine and apoptotic signatures in patients with hepatitis C, Translational Research 149 (2007), 126-136.
24. K. Patel, S.C. Gordon, I. Jacobson et al., Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients, J Hepatology 41 (2004), 935-942.
25. T. Poynard, V. Ratziu, Y. Benmanov et al., Fibrosis in patients with chronic hepatitis C: detection and significance, Seminars Liver Disease 20 (2000), 47-55.
26. T. Reiberger, J.H. Aberle, M. Kundi et al., IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIVHCV coinfection, Antiviral Therapy 13 (2008), 969-976.
27. A.I. Romero, M. Lagging, J. Westin et al., Interferon (IFN)- ?-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-?2a and ribavirin for chronic hepatitis C virus infection, J Infectious Disease 194 (2006), 895-903.
28. P.J. Scheuer, Classification of chronic viral hepatitis: a need for reassessment, J Hepatology 13 (1991), 372-374.
29. E. Schvoerer, M.C. Navas, C. Thumann et al., Production of interleukin-18 and interleukin-12 in patients suffering from chronic hepatitis C virus infection before antiviral therapy, J Medical Virology 70 (2003), 588-593.
30. H. Shirakawa, A. Matsumoto, S. Joshita et al., Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors, Hepatology 48 (2008), 1753-17560.
31. R. Sugimoto, M. Enjoji, M. Nakamuta et al., Effect of IL-4 and IL-13 on collagen production in cultured LI90 human hepatic stellate cells, Liver International 25 (2005), 420-428.
32. H. Tsushima, S. Kawata, S. Tamura et al., Reduced plasma transforming growth factor-beta1 levels in patients with chronic hepatitis C after interferon-alpha therapy: association with regression of hepatic fibrosis, J Hepatology 30 (1999), 1-7.
33. V. Verma, A. Chakravarti and P. Kar, Cytokine levels of TGFbeta, IL-10 and sTNFalphaRII in type C chronic liver disease, Digestive Disease Science 53 (2008), 2233-2237.
34. L. Wan, Y.J. Kung, Y.J. Lin et al., Th1 and Th2 cytokines are elevated in HCV-infected SVR(-) patients treated with interferon-alpha, Biochem Biophys Research Communication 379 (2009), 855-860.
35. M.W. Watson, A. Jaksic, P. Price et al., Interferon-gamma response by peripheral blood mononuclear cells to hepatitis C virus core antigen is reduced in patients with liver fibrosis, J Infect Disease 188 (2003), 1533-1536.
36. T.A. Wynn, Fibrotic disease and the T(H)1/T(H)2 paradigm, Nature Review Immunology 4 (2004), 583-594.
37. S.S. Yang, L.S. Fu, C.S. Chang, H.Z. Yeh, G.H. Chen and J.H. Kao, Changes of soluble CD26 and CD30 levels correlate with response to interferon plus ribavirin therapy in patients with chronic hepatitis C, J Gastroenterology Hepatology 21 (2006), 1789-1793.
38. M. Zeremski, M. Markatou, Q.B. Brown and G. Dorante, Cunningham-Rundles S and Talal AH. Interferon gammainducible protein 10: a predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected patients, J Acquired Immune Deficiency Syndrome 45 (2007), 262-268.
39. M. Zeremski, L.M. Petrovic and A.H. Talal, The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection, J Viral Hepatology 14 (2007), 675-687.